Beyond Obesity: Lilly Inks Up to $11.25B in Cancer, Immune System Deals

Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B

The next frontier for cell therapy is shaping up to be in vivo treatments for autoimmune disease, and Eli Lilly is getting a contender through the acquisition of startup Orna Therapeutics for up to $2.4 billion.The companies did not provide a financial breakdown of the deal in their Monday announcement, saying only that the sum encompasses an upfront payment and milestone payments tied to clinical development. Orna’s lead program is approaching …

Beyond Obesity: Lilly Inks Up to $11.25B in Cancer, Immune System Deals

Flush with cash from its obesity/diabetes dual blockbuster tirzepatide, Eli Lilly signaled earlier this month that it intended to invest some of that money into new deals to strengthen its pipelines in oncology, neuroscience, and immunology. Lilly has begun delivering on that promise through a pair of business development deals announced this week. The pharma giant said it will shell out $2.4 billion to acquire genetic medicine developer Orna Th…